AKOYA BIOSCIENCES, INC. Financials Akoya Biosciences, Inc.
Equities
AKYA
US00974H1041
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.86 USD | 0.00% |
|
+1.31% | -20.90% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 569.7 | 363.2 | 239.5 | 190.6 | - | - |
| Enterprise Value (EV) 1 | 489 | 363.2 | 230.9 | 177.9 | 175.9 | 181.8 |
| P/E ratio | -9.28 x | -5.12 x | -3.41 x | -4.6 x | -7.37 x | -16.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 10.4 x | 4.85 x | 2.48 x | 1.65 x | 1.39 x | 1.17 x |
| EV / Revenue | 8.91 x | 4.85 x | 2.39 x | 1.54 x | 1.28 x | 1.12 x |
| EV / EBITDA | -14.1 x | -6.12 x | -4.66 x | -6.72 x | -15.1 x | 49.4 x |
| EV / FCF | -11.9 x | -5.97 x | -4.23 x | -5.56 x | -168 x | -145 x |
| FCF Yield | -8.42% | -16.8% | -23.6% | -18% | -0.6% | -0.69% |
| Price to Book | 4.72 x | 6.17 x | 4.03 x | 6.86 x | 10.1 x | 7.41 x |
| Nbr of stocks (in thousands) | 37,208 | 37,956 | 49,076 | 49,380 | - | - |
| Reference price 2 | 15.31 | 9.570 | 4.880 | 3.860 | 3.860 | 3.860 |
| Announcement Date | 3/14/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 42.44 | 54.92 | 74.86 | 96.63 | 115.7 | 137.1 | 162.6 |
| EBITDA 1 | - | -34.57 | -59.37 | -49.6 | -26.49 | -11.68 | 3.681 |
| EBIT 1 | - | -39.3 | -66.11 | -57.67 | -36.07 | -20.7 | -5.121 |
| Operating Margin | - | -71.56% | -88.31% | -59.68% | -31.18% | -15.1% | -3.15% |
| Earnings before Tax (EBT) 1 | - | -43.08 | -70.52 | -63.28 | -40.06 | -24.67 | -11.08 |
| Net income 1 | -16.71 | -44.37 | -70.64 | -63.32 | -41.44 | -26.54 | -11.45 |
| Net margin | -39.36% | -80.79% | -94.37% | -65.53% | -35.82% | -19.36% | -7.04% |
| EPS 2 | -9.180 | -1.650 | -1.870 | -1.430 | -0.8388 | -0.5238 | -0.2300 |
| Free Cash Flow 1 | - | -41.16 | -60.86 | -54.55 | -32 | -1.05 | -1.25 |
| FCF margin | - | -74.95% | -81.29% | -56.45% | -27.66% | -0.77% | -0.77% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/26/21 | 3/14/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.48 | 16.16 | 16.89 | 17.89 | 18.85 | 21.22 | 21.41 | 23.52 | 25.22 | 26.49 | 24.28 | 27.54 | 30.16 | 33.75 | 30.04 |
| EBITDA 1 | -9.495 | -15.41 | -14.01 | -14.69 | -14.84 | -15.83 | -15.46 | -17.4 | -9.176 | -7.565 | -10.77 | -7.333 | -5.3 | -3.6 | -4.1 |
| EBIT 1 | -10.74 | -16.78 | -15.55 | -16.31 | -16.65 | -17.59 | -17.44 | -19.24 | -11.55 | -9.439 | -13.1 | -10.45 | -7.631 | -5.157 | -8.251 |
| Operating Margin | -79.69% | -103.85% | -92.07% | -91.14% | -88.34% | -82.9% | -81.44% | -81.81% | -45.81% | -35.64% | -53.96% | -37.94% | -25.3% | -15.28% | -27.47% |
| Earnings before Tax (EBT) 1 | -11.63 | -17.79 | -16.38 | -17.39 | -17.85 | -18.9 | -18.77 | -20.78 | -12.9 | -10.82 | -14.07 | -11.49 | -8.449 | -5.946 | -9.628 |
| Net income 1 | -11.62 | -17.67 | -16.4 | -17.5 | -17.87 | -18.88 | -18.8 | -20.8 | -12.92 | -10.8 | -14.28 | -11.78 | -8.901 | -6.426 | -9.849 |
| Net margin | -86.21% | -109.38% | -97.07% | -97.77% | -94.8% | -88.95% | -87.82% | -88.44% | -51.22% | -40.78% | -58.8% | -42.76% | -29.51% | -19.04% | -32.79% |
| EPS 2 | -0.3100 | -0.4700 | -0.4400 | -0.4700 | -0.4700 | -0.5000 | -0.4900 | -0.5100 | -0.2600 | -0.2200 | -0.2888 | -0.2362 | -0.1800 | -0.1350 | -0.1917 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/14/22 | 5/5/22 | 8/8/22 | 11/7/22 | 3/6/23 | 5/8/23 | 8/7/23 | 11/8/23 | 3/4/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 80.6 | - | 8.57 | 12.7 | 14.7 | 8.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -41.2 | -60.9 | -54.6 | -32 | -1.05 | -1.25 |
| ROE (net income / shareholders' equity) | - | -126% | -78.5% | -113% | -104% | -114% | -9.06% |
| ROA (Net income/ Total Assets) | - | -33% | -38.5% | -35.5% | -27.3% | -16% | -3.84% |
| Assets 1 | - | 134.3 | 183.5 | 178.2 | 152 | 166.1 | 298.2 |
| Book Value Per Share 2 | - | 3.240 | 1.550 | 1.210 | 0.5600 | 0.3800 | 0.5200 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 5.09 | 7.36 | 3.65 | 6.45 | 7.05 | 7.75 |
| Capex / Sales | - | 9.28% | 9.83% | 3.78% | 5.58% | 5.14% | 4.76% |
| Announcement Date | 3/26/21 | 3/14/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.86
USD
Average target price
9
USD
Spread / Average Target
+133.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.90% | 191M | |
| +8.69% | 220B | |
| +6.69% | 183B | |
| +10.90% | 133B | |
| +25.41% | 107B | |
| -1.06% | 63.05B | |
| +12.72% | 51.74B | |
| +3.96% | 50.47B | |
| +0.40% | 40.91B | |
| +15.03% | 40.59B |
- Stock Market
- Equities
- AKYA Stock
- Financials Akoya Biosciences, Inc.
